Switch to:
Also traded in: Germany, Switzerland

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt No Debt
HEB's Cash-to-Debt is ranked higher than
96% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. HEB: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
HEB' s Cash-to-Debt Range Over the Past 10 Years
Min: 2.31  Med: 9455 Max: No Debt
Current: No Debt
Equity-to-Asset 0.82
HEB's Equity-to-Asset is ranked higher than
63% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. HEB: 0.82 )
Ranked among companies with meaningful Equity-to-Asset only.
HEB' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.35  Med: 0.87 Max: 0.93
Current: 0.82
0.35
0.93
Interest Coverage No Debt
HEB's Interest Coverage is ranked lower than
99.99% of the 453 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. HEB: No Debt )
Ranked among companies with meaningful Interest Coverage only.
HEB' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 3
Altman Z-Score: -20.77
Beneish M-Score: -3.74
WACC vs ROIC
0.07%
-134.67%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -15004.35
HEB's Operating Margin % is ranked lower than
93% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. HEB: -15004.35 )
Ranked among companies with meaningful Operating Margin % only.
HEB' s Operating Margin % Range Over the Past 10 Years
Min: -15004.35  Med: -10569.8 Max: -1821.44
Current: -15004.35
-15004.35
-1821.44
Net Margin % -8154.35
HEB's Net Margin % is ranked lower than
92% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. HEB: -8154.35 )
Ranked among companies with meaningful Net Margin % only.
HEB' s Net Margin % Range Over the Past 10 Years
Min: -11451.13  Med: -8150.89 Max: -1712.84
Current: -8154.35
-11451.13
-1712.84
ROE % -42.43
HEB's ROE % is ranked lower than
59% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. HEB: -42.43 )
Ranked among companies with meaningful ROE % only.
HEB' s ROE % Range Over the Past 10 Years
Min: -79.37  Med: -42.92 Max: -20.44
Current: -42.43
-79.37
-20.44
ROA % -35.16
HEB's ROA % is ranked lower than
59% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. HEB: -35.16 )
Ranked among companies with meaningful ROA % only.
HEB' s ROA % Range Over the Past 10 Years
Min: -67.22  Med: -36.12 Max: -18.36
Current: -35.16
-67.22
-18.36
ROC (Joel Greenblatt) % -72.80
HEB's ROC (Joel Greenblatt) % is ranked higher than
64% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. HEB: -72.80 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
HEB' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -379.52  Med: -185.43 Max: -72.3
Current: -72.8
-379.52
-72.3
3-Year Revenue Growth Rate -28.60
HEB's 3-Year Revenue Growth Rate is ranked lower than
77% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: 5.10 vs. HEB: -28.60 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
HEB' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -59.5  Med: -11.5 Max: 59.4
Current: -28.6
-59.5
59.4
3-Year EBITDA Growth Rate -36.30
HEB's 3-Year EBITDA Growth Rate is ranked lower than
74% of the 534 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. HEB: -36.30 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
HEB' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -36.3  Med: -6.3 Max: 93.1
Current: -36.3
-36.3
93.1
3-Year EPS without NRI Growth Rate -34.30
HEB's 3-Year EPS without NRI Growth Rate is ranked lower than
72% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. HEB: -34.30 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
HEB' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -39.1  Med: -6.1 Max: 21.1
Current: -34.3
-39.1
21.1
GuruFocus has detected 3 Warning Signs with Hemispherx Biopharma Inc $HEB.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» HEB's 10-Y Financials

Financials (Next Earnings Date: 2017-06-29 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

HEB Guru Trades in

HEB Guru Trades in

Q3 2016

HEB Guru Trades in Q3 2016

Jim Simons 158,152 sh (New)
» More
Q4 2016

HEB Guru Trades in Q4 2016

Jim Simons 139,952 sh (-11.51%)
» More
» Details

Insider Trades

Latest Guru Trades with HEB

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:OTCPK:ENDV, NAS:KTOV, NAS:SNGX, OTCPK:BCTXF, OTCPK:OPNT, NAS:CYCC, NAS:TENX, NAS:MBVX, OTCPK:VRTHF, NAS:CLSN, NAS:APTO, OTCPK:MBXBF, OTCPK:ENUM, OTCPK:CDXI, NAS:GNVC, OTCPK:ATTBF, NAS:RTTR, NAS:SBOT, NAS:BSTG, OTCPK:SARSF » details
Traded in other countries:HXB1.Germany, HEB.Switzerland,
Headquarter Location:USA
Hemispherx Biopharma Inc is a specialty pharmaceutical company. It is engaged in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders.

Hemispherx Biopharma Inc is a Delaware Corporation founded in the early 1970s. The Company is a specialty pharmaceutical company. It is engaged in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. Since its inception, it has established a foundation of laboratory, pre-clinical and clinical data with respect to the development of natural interferon and nucleic acids to enhance the natural antiviral defense system of the human body and to aid the development of therapeutic products for the treatment of certain chronic diseases. The Company owns and operates a 43,000 sq. ft. manufacturing facility in New Brunswick, NJ that produces Alferon and Ampligen. The Company operates in one segment, which performs research and development activities related to Ampligen and other drugs under development, and sales and marketing of Alferon. The Company's primary pharmaceutical product platform consists of its experimental compound, Ampligen, its FDA approved natural interferon product, Alferon N Injection and, its experimental liquid natural interferon for oral administration, Alferon LDO (Low Dose Oral). As of December 31, 2013, the Company had 25 patents. Its potential competitors are among the pharmaceutical companies in the world, are well known to the public and the medical community, and have substantially greater financial resources, product development, and manufacturing and marketing capabilities. The Company is subject to various federal, state and local laws, regulations and recommendations relating to such matters as safe working conditions, laboratory and manufacturing practices, the experimental use of animals and the use of and disposal of hazardous or potentially hazardous substances, including radioactive compounds and infectious disease agents, used in connection with its research work.

Top Ranked Articles about Hemispherx Biopharma Inc

Hemispherx Biopharma Announces Financial Results for the Year Ended December 31, 2016
Hemispherx Biopharma, Inc. Meets Ampligen Sales Milestone in the 1st Quarter of 2017

PHILADELPHIA, March 06, 2017 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. ( MKT:HEB) (the “Company” or “Hemispherx”) announced today that it has met a major milestone, the commencement of sales of recently manufactured Ampligen in international programs. Hemispherx has also reinitiated its US-based cost recovery program at the price increase recently approved by the FDA. Hemispherx has initiated an accelerated production plan with both its primary and secondary contract manufacturers in order to meet the anticipated future demand for Ampligen in both international programs as well as cost recovery programs.
“In the last quarter of 2016, we began manufacturing new lots of Ampligen. As I mentioned in our last stockholders call, we anticipated generating sales from our newly manufactured lots of Ampligen in the first quarter of 2017.  Mission accomplished! We will continue to aggressively pursue this path while we seek FDA approval of Ampligen in the United States,” said Tom Equels, CEO of Hemispherx. About Hemispherx Biopharma
Hemispherx Biopharma, Inc. is an advanced specialty pharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of seriously debilitating disorders. Hemispherx’s flagship products include Alferon N Injection® and the experimental therapeutics rintatolimod (tradenames Ampligen® or Rintamod®) and Alferon® LDO. Rintatolimod is an experimental RNA nucleic acid being developed for globally important debilitating diseases and disorders of the immune system, including Chronic Fatigue Syndrome. Hemispherx’s platform technology includes components for potential treatment of various severely debilitating and life threatening diseases. Because both rintatolimod and Alferon® LDO are experimental in nature, they are not designated safe and effective by the FDA for general use and are legally available only through clinical trials. Hemispherx has patents comprising its core intellectual property estate and a fully commercialized product (Alferon N Injection®), approved for sale in the U.S. and Argentina. The FDA approval of Alferon N Injection® is limited to the treatment of refractory or recurrent external genital warts in patients 18 years of age or older. Our Alferon N® approval in Argentina includes the use of Alferon N Injection® (under the pending brand name “Naturaferon”) for use in any patients who fail or become intolerant to recombinant interferon, including patients with chronic active hepatitis C infection. Rintamod® has received approval in the Argentine Republic to treat severe cases of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). It will be marketed by GP Pharm, Hemispherx’s commercial partner in Latin America. Hemispherx wholly owns and exclusively operates a GMP certified manufacturing facility in the United States for commercial products. For more information please visit www.hemispherx.net. Forward-Looking Statements
To the extent that statements in this press release are not strictly historical, all such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as “intends”, “plans”, “potential”, “potentially”, “possible” and similar expressions are intended to identify forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Hemispherx that any of its plans will be achieved. These forward-looking statements are neither promises nor guarantees of future performance, and are subject to a variety of risks and uncertainties, many of which are beyond Hemispherx’s control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. Examples of such risks and uncertainties include those set forth in the Disclosure Notice, below, market and other conditions, the impact of general economic, industry or political conditions in the United States or internationally, as well as the risks described in Hemispherx’s filings with the Securities and Exchange Commission, including the most recent reports on Forms 10-K, 10-Q and 8-K. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Hemispherx undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise revise or update this release to reflect events or circumstances after the date hereof. Disclosure Notice
The information in this press release includes certain "forward-looking” statements including without limitation statements about additional steps which the FDA may require and Hemispherx may take in continuing to seek commercial approval of the Ampligen® NDA for the treatment of Chronic Fatigue Syndrome in the United States. The final results of these and other ongoing activities could vary materially from Hemispherx’s expectations and could adversely affect the chances for approval of the Ampligen® NDA in the United States and other countries. The clinical studies referenced herein have been previously reviewed by the FDA and are not, in and of themselves, a sufficient basis for approval in the United States. Any failure to satisfy the FDA regulatory requirements or the requirements of other countries could significantly delay, or preclude outright, approval of the Ampligen® NDA in the United States and other countries. Information contained in this news release, other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties including, but not limited to, general industry conditions and competition; general economic factors; our ability to adequately fund our projects; the impact of pharmaceutical industry regulation and healthcare legislation in the United States and internationally; trends toward healthcare cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; our ability to accurately predict the future market conditions; manufacturing difficulties or delays; dependence on the effectiveness of our patents and other protections for products; and the exposure to litigation, including patent litigation, and/or regulatory actions; and numerous other factors discussed in this release and in our filings with the Securities and Exchange Commission. The production of new Alferon® API inventory will not commence until the validation phase is complete. While the facility is approved by FDA under the Biological License Application ("BLA”) for Alferon®, this status will need to be reaffirmed by a successful Pre-Approval Inspection by the FDA prior to commercial sale of newly produced inventory product. The validation phase was delayed because of the damage caused by the flood that occurred in January 2016 at the facility. At this time, we believe that all repairs to the manufacturing facility have been completed. If and when we obtain a reaffirmation of FDA BLA status and have begun production of new Alferon® API, we will need FDA approval as to the quality and stability of the final product to allow commercial sales to resume. With regard to our NDA for Ampligen® to treat CFS, we note that there are additional steps which the FDA has advised us to take in our seeking approval. The final results of these efforts and/or any other activities could vary materially from our expectations. Any failure to satisfy the FDA regulatory requirements or the requirements of other countries could significantly delay, or preclude outright, approval of Ampligen® in the United States and other countries. No evidence is suggested that Ampligen® will be commercially approved for any treatment or that Alferon N Injection® will be commercially approved for potential new treatment indications or for new manufacturing procedures. Approval of Rintamod® for CFS in the Argentine Republic does not in any way suggest that the Ampligen® NDA in the United States will obtain commercial approval. Also, it is noted that ANMAT approval is only an initial, but important, step in the overall successful commercialization. Namely, additional steps required for commercialization in Argentina will require, among others, an appropriate reimbursement level, appropriate marketing strategies, completion of manufacturing preparations for launch (including possible requirements for approval of final manufacturing, etc., and there are no assurances as to whether or when such multiple subsequent steps will be successfully performed to result in an overall successful commercialization and product launch).
Company/Investor Contact:
Charles Jones
CJones & Associates Public Relations
888-557-6480
[email protected]

Read more...

Ratios

vs
industry
vs
history
PB Ratio 1.04
HEB's PB Ratio is ranked higher than
95% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. HEB: 1.04 )
Ranked among companies with meaningful PB Ratio only.
HEB' s PB Ratio Range Over the Past 10 Years
Min: 0.6  Med: 1.8 Max: 13.74
Current: 1.04
0.6
13.74
PS Ratio 134.00
HEB's PS Ratio is ranked lower than
86% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.47 vs. HEB: 134.00 )
Ranked among companies with meaningful PS Ratio only.
HEB' s PS Ratio Range Over the Past 10 Years
Min: 44.49  Med: 239 Max: 2630.77
Current: 134
44.49
2630.77
EV-to-EBIT -1.42
HEB's EV-to-EBIT is ranked lower than
99.99% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. HEB: -1.42 )
Ranked among companies with meaningful EV-to-EBIT only.
HEB' s EV-to-EBIT Range Over the Past 10 Years
Min: -18.4  Med: -2.2 Max: 1
Current: -1.42
-18.4
1
EV-to-EBITDA -1.75
HEB's EV-to-EBITDA is ranked lower than
99.99% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. HEB: -1.75 )
Ranked among companies with meaningful EV-to-EBITDA only.
HEB' s EV-to-EBITDA Range Over the Past 10 Years
Min: -19.2  Med: -2.3 Max: 1.1
Current: -1.75
-19.2
1.1
Current Ratio 2.85
HEB's Current Ratio is ranked lower than
52% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. HEB: 2.85 )
Ranked among companies with meaningful Current Ratio only.
HEB' s Current Ratio Range Over the Past 10 Years
Min: 1.37  Med: 5.75 Max: 22.33
Current: 2.85
1.37
22.33
Quick Ratio 2.85
HEB's Quick Ratio is ranked higher than
50% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. HEB: 2.85 )
Ranked among companies with meaningful Quick Ratio only.
HEB' s Quick Ratio Range Over the Past 10 Years
Min: 1.37  Med: 5.48 Max: 22.33
Current: 2.85
1.37
22.33
Days Inventory 349.45
HEB's Days Inventory is ranked lower than
89% of the 436 Companies
in the Global Biotechnology industry.

( Industry Median: 126.28 vs. HEB: 349.45 )
Ranked among companies with meaningful Days Inventory only.
HEB' s Days Inventory Range Over the Past 10 Years
Min: 67  Med: 218.41 Max: 349.45
Current: 349.45
67
349.45
Days Payable 292.20
HEB's Days Payable is ranked higher than
88% of the 409 Companies
in the Global Biotechnology industry.

( Industry Median: 58.37 vs. HEB: 292.20 )
Ranked among companies with meaningful Days Payable only.
HEB' s Days Payable Range Over the Past 10 Years
Min: 277.06  Med: 385.89 Max: 808.75
Current: 292.2
277.06
808.75

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -20.10
HEB's 3-Year Average Share Buyback Ratio is ranked lower than
60% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. HEB: -20.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
HEB' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -25.7  Med: -14.6 Max: -4.9
Current: -20.1
-25.7
-4.9

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 6.70
HEB's Price-to-Net-Cash is ranked higher than
67% of the 514 Companies
in the Global Biotechnology industry.

( Industry Median: 6.54 vs. HEB: 6.70 )
Ranked among companies with meaningful Price-to-Net-Cash only.
HEB' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.06  Med: 7.98 Max: 170.4
Current: 6.7
1.06
170.4
Price-to-Net-Current-Asset-Value 4.47
HEB's Price-to-Net-Current-Asset-Value is ranked higher than
76% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 6.07 vs. HEB: 4.47 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
HEB' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.01  Med: 7.27 Max: 34.54
Current: 4.47
1.01
34.54
Price-to-Tangible-Book 1.12
HEB's Price-to-Tangible-Book is ranked higher than
96% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. HEB: 1.12 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
HEB' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.71  Med: 5.37 Max: 26
Current: 1.12
0.71
26
Price-to-Median-PS-Value 0.56
HEB's Price-to-Median-PS-Value is ranked higher than
80% of the 584 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. HEB: 0.56 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
HEB' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.04  Med: 0.7 Max: 2.34
Current: 0.56
0.04
2.34
Earnings Yield (Greenblatt) % -69.80
HEB's Earnings Yield (Greenblatt) % is ranked lower than
84% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. HEB: -69.80 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
HEB' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -89.34  Med: 396.7 Max: 2162.6
Current: -69.8
-89.34
2162.6

More Statistics

Revenue (TTM) (Mil) $0.09
EPS (TTM) $ -0.41
Beta-0.36
Short Percentage of Float2.13%
52-Week Range $0.39 - 2.64
Shares Outstanding (Mil)24.11

Analyst Estimate

Dec17 Dec18
Revenue (Mil $)
EPS ($) 0.24 0.48
EPS without NRI ($) 0.24 0.48
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for HEB

Headlines

Articles On GuruFocus.com
Hemispherx Biopharma Announces Financial Results for the Year Ended December 31, 2016 Mar 31 2017 
Hemispherx Biopharma, Inc. Meets Ampligen Sales Milestone in the 1st Quarter of 2017 Mar 06 2017 
Hemispherx Biopharma Inc Reports Operating Results (10-Q/A) Feb 14 2011 
Hemispherx Biopharma Inc Reports Operating Results (10-K/A) Feb 14 2011 
Hemispherx Biopharma Inc Reports Operating Results (10-Q/A) Feb 14 2011 
Hemispherx Biopharma Inc Reports Operating Results (10-Q/A) Feb 14 2011 
Hemispherx Biopharma Inc Reports Operating Results (10-Q) Nov 08 2010 
Weekly CEO Sells Highlight: Hemispherx Biopharma Inc, ADESA Inc, Entergy Corp, and Danaher Corp. Aug 15 2010 
Hemispherx Biopharma Inc Reports Operating Results (10-Q) Aug 06 2010 
Hemispherx Biopharma Inc (HEB) CEO William A Carter buys 500,000 Shares Jul 01 2010 

More From Other Websites
Edited Transcript of HEB earnings conference call or presentation 7-Apr-17 3:00pm GMT Apr 21 2017
ETFs with exposure to Hemispherx Biopharma, Inc. : April 19, 2017 Apr 19 2017
Hemispherx Biopharma, Inc. :HEB-US: Earnings Analysis: Q4, 2016 By the Numbers : April 5, 2017 Apr 05 2017
Hemispherx Biopharma Announces Financial Results for the Year Ended December 31, 2016 Mar 31 2017
Hemispherx Biopharma, Inc. Meets Ampligen Sales Milestone in the 1st Quarter of 2017 Mar 06 2017
Why President Trump Wants To Transform The FDA – And What It Could Mean For Biotech Stocks Feb 23 2017
$1M deal: Hemispherx plans to sell stock, warrants Feb 03 2017
Hemispherx Biopharma, Inc. Announces $1 Million Registered Direct Offering Feb 02 2017
ETFs with exposure to Hemispherx Biopharma, Inc. : January 3, 2017 Jan 03 2017
ETFs with exposure to Hemispherx Biopharma, Inc. : December 8, 2016 Dec 08 2016
Crystal Research Associates, LLC Issues Executive Informational Overview on Hemispherx Biopharma,... Dec 01 2016
ETFs with exposure to Hemispherx Biopharma, Inc. : November 23, 2016 Nov 23 2016
Hemispherx Biopharma, Inc. :HEB-US: Earnings Analysis: Q3, 2016 By the Numbers : November 21, 2016 Nov 21 2016
Hemispherx 3Q Loss $2.9M or 13 Cents a Share (HEB) Nov 16 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)